{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:42:16Z","timestamp":1791906136764,"version":"4.3.4"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180472"],"award-info":[{"award-number":["RP180472"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0728-4","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T07:05:02Z","timestamp":1568790302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer"],"prefix":"10.1136","volume":"7","author":[{"given":"Stephanie","family":"Dorta-Estremera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh L.","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravaen B.","family":"Slay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananta V.","family":"Yanamandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita","family":"Nookala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Jagannadha","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"issue":"29","key":"728_CR1","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","volume":"33","author":"ML Gillison","year":"2015","unstructured":"Gillison ML, et al. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235\u201342.","journal-title":"J Clin Oncol"},{"issue":"32","key":"728_CR2","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","volume":"29","author":"AK Chaturvedi","year":"2011","unstructured":"Chaturvedi AK, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294\u2013301.","journal-title":"J Clin Oncol"},{"issue":"1","key":"728_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/coa.12895","volume":"43","author":"V Dogan","year":"2018","unstructured":"Dogan V, et al. Current studies of immunotherapy in head and neck cancer. Clin Otolaryngol. 2018;43(1):13\u201321.","journal-title":"Clin Otolaryngol"},{"issue":"10","key":"728_CR4","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1084\/jem.20100637","volume":"207","author":"J Fourcade","year":"2010","unstructured":"Fourcade J, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175\u201386.","journal-title":"J Exp Med"},{"issue":"5","key":"728_CR5","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"JM Chauvin","year":"2015","unstructured":"Chauvin JM, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 2015;125(5):2046\u201358.","journal-title":"J Clin Invest"},{"issue":"1","key":"728_CR6","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2018","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2018;7(1):e1364828.","journal-title":"Oncoimmunology"},{"issue":"6","key":"728_CR7","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","volume":"73","author":"S Lyford-Pike","year":"2013","unstructured":"Lyford-Pike S, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733\u201341.","journal-title":"Cancer Res"},{"key":"728_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568.","journal-title":"Nature"},{"issue":"12","key":"728_CR9","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","volume":"23","author":"JH Yearley","year":"2017","unstructured":"Yearley JH, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in Cancer. Clin Cancer Res. 2017;23(12):3158\u201367.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"728_CR10","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1158\/0008-5472.CAN-18-0892","volume":"78","author":"S Dorta-Estremera","year":"2018","unstructured":"Dorta-Estremera S, et al. Mucosal HPV E6\/E7 peptide vaccination in combination with immune checkpoint modulation induces regression of HPV(+) Oral cancers. Cancer Res. 2018;78(18):5327\u201339.","journal-title":"Cancer Res"},{"issue":"38","key":"728_CR11","doi-asserted-by":"publisher","first-page":"E5290","DOI":"10.1073\/pnas.1514418112","volume":"112","author":"T Bartkowiak","year":"2015","unstructured":"Bartkowiak T, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6\/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015;112(38):E5290\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"728_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ijos.2014.48","volume":"6","author":"R-Q Wu","year":"2014","unstructured":"Wu R-Q, et al. The mucosal immune system in the oral cavity\u2014an orchestra of T cell diversity. Int J Oral Sci. 2014;6(3):125\u201332.","journal-title":"Int J Oral Sci"},{"issue":"4","key":"728_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.it.2017.08.005","volume":"39","author":"NM Moutsopoulos","year":"2018","unstructured":"Moutsopoulos NM, Konkel JE. Tissue-specific immunity at the Oral mucosal barrier. Trends Immunol. 2018;39(4):276\u201387.","journal-title":"Trends Immunol"},{"issue":"7","key":"728_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/hed.21040","volume":"31","author":"R Williams","year":"2009","unstructured":"Williams R, et al. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck. 2009;31(7):911\u20138.","journal-title":"Head Neck"},{"issue":"4","key":"728_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, et al. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417\u20139.","journal-title":"Nat Methods"},{"issue":"12","key":"728_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"1","key":"728_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","volume":"73","author":"C Badoual","year":"2013","unstructured":"Badoual C, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73(1):128\u201338.","journal-title":"Cancer Res"},{"issue":"7528","key":"728_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.","journal-title":"Nature"},{"issue":"4","key":"728_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/his.13646","volume":"73","author":"S Schneider","year":"2018","unstructured":"Schneider S, et al. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. Histopathology. 2018;73(4):573\u201384.","journal-title":"Histopathology"},{"issue":"5","key":"728_CR20","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","volume":"186","author":"S Terawaki","year":"2011","unstructured":"Terawaki S, et al. IFN-\u03b1 directly promotes programmed cell Death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol. 2011;186(5):2772\u20139.","journal-title":"J Immunol"},{"issue":"2","key":"728_CR21","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.18632\/oncotarget.13895","volume":"8","author":"Y Dong","year":"2017","unstructured":"Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8(2):2171\u201386.","journal-title":"Oncotarget"},{"issue":"7265","key":"728_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461(7265):788\u201392.","journal-title":"Nature"},{"issue":"7","key":"728_CR23","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018\u201330.","journal-title":"Cell Rep"},{"issue":"6","key":"728_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2326-6066.CIR-16-0284","volume":"5","author":"JB Foote","year":"2017","unstructured":"Foote JB, et al. A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in Tolerized mice. Cancer Immunol Res. 2017;5(6):468\u201379.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"728_CR25","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","volume":"25","author":"KE Sivick","year":"2018","unstructured":"Sivick KE, et al. Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity. Cell Rep. 2018;25(11):3074\u201385 e5.","journal-title":"Cell Rep"},{"issue":"8","key":"728_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1158\/2326-6066.CIR-17-0049","volume":"5","author":"CR Ager","year":"2017","unstructured":"Ager CR, et al. Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity. Cancer Immunol Res. 2017;5(8):676\u201384.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"728_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/2326-6066.CIR-16-0365","volume":"5","author":"HY Li","year":"2017","unstructured":"Li HY, et al. The tumor microenvironment regulates sensitivity of murine lung tumors to PD-1\/PD-L1 antibody blockade. Cancer Immunol Res. 2017;5(9):767\u201377.","journal-title":"Cancer Immunol Res"},{"key":"728_CR28","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1200\/JCO.2017.35.15_suppl.6012","volume":"35","author":"R Uppaluri","year":"2017","unstructured":"Uppaluri R, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2017;35:6012.","journal-title":"J Clin Oncol"},{"issue":"1","key":"728_CR29","first-page":"29","volume":"86","author":"ML Walker","year":"1994","unstructured":"Walker ML. The operative and nonoperative management of blunt liver injury. J Natl Med Assoc. 1994;86(1):29\u201332.","journal-title":"J Natl Med Assoc"},{"issue":"14","key":"728_CR30","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml J, et al. Pembrolizumab for platinum- and Cetuximab-refractory head and neck Cancer: results from a single-arm, Phase II Study. J Clin Oncol. 2017;35(14):1542\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"728_CR31","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","volume":"18","author":"KJ Harrington","year":"2017","unstructured":"Harrington KJ, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18(8):1104\u201315.","journal-title":"Lancet Oncol"},{"issue":"19","key":"728_CR32","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367.","journal-title":"N Engl J Med"},{"issue":"32","key":"728_CR33","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","volume":"34","author":"LQM Chow","year":"2016","unstructured":"Chow LQM, et al. Antitumor activity of Pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838\u201345.","journal-title":"J Clin Oncol"},{"issue":"1","key":"728_CR34","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","volume":"6","author":"RY Huang","year":"2017","unstructured":"Huang RY, et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6(1):e1249561.","journal-title":"Oncoimmunology"},{"issue":"4","key":"728_CR35","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo SR, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917\u201327.","journal-title":"Cancer Res"},{"issue":"6","key":"728_CR36","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei SC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170(6):1120\u201333 e17.","journal-title":"Cell"},{"issue":"8","key":"728_CR37","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1084\/jem.20082492","volume":"206","author":"KS Peggs","year":"2009","unstructured":"Peggs KS, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717\u201325.","journal-title":"J Exp Med"},{"issue":"17","key":"728_CR38","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1073\/pnas.1003345107","volume":"107","author":"J Matsuzaki","year":"2010","unstructured":"Matsuzaki J, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107(17):7875\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"728_CR39","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0959-8049(01)00184-8","volume":"37","author":"CE Demeure","year":"2001","unstructured":"Demeure CE, et al. T lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3\/MHC class II interactions in cell-cell contacts. Eur J Cancer. 2001;37(13):1709\u201318.","journal-title":"Eur J Cancer"},{"issue":"6","key":"728_CR40","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E Martin De","year":"2018","unstructured":"De Martin E, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68(6):1181\u201390.","journal-title":"J Hepatol"},{"issue":"4","key":"728_CR41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G Velasco De","year":"2017","unstructured":"De Velasco G, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in Cancer patients. Cancer Immunol Res. 2017;5(4):312\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"728_CR42","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"8","key":"728_CR43","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340.","journal-title":"J Clin Invest"},{"issue":"15","key":"728_CR44","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/jco.2015.33.15_suppl.3001","volume":"33","author":"A Ribas","year":"2015","unstructured":"Ribas A, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol. 2015;33(15):3001.","journal-title":"J Clin Oncol"},{"issue":"5","key":"728_CR45","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830\u201342.","journal-title":"Immunity"},{"key":"728_CR46","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"issue":"12","key":"728_CR47","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-16-0104","volume":"4","author":"E Moore","year":"2016","unstructured":"Moore E, et al. Established T cell-inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade. Cancer Immunol Res. 2016;4(12):1061\u201371.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"728_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1338997","volume":"6","author":"M Nikanjam","year":"2017","unstructured":"Nikanjam M, Patel H, Kurzrock R. Dosing immunotherapy combinations: analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology. 2017;6(8):e1338997.","journal-title":"Oncoimmunology"},{"issue":"7736","key":"728_CR49","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","volume":"564","author":"JM Ramanjulu","year":"2018","unstructured":"Ramanjulu JM, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564(7736):439\u201343.","journal-title":"Nature"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0728-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:45:19Z","timestamp":1601041519000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0728-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0728-4","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"assertion":[{"value":"15 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}